 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment closed, Enrollment change, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Dec 19, 2023
P1, N=10, Active, not recruiting, Sponsor: Seattle Children's Hospital
Recruiting --> Active, not recruiting | N=48 --> 10
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Trial completion date, Trial primary completion date, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Mar 15, 2021
P1, N=48, Recruiting, Sponsor: Seattle Children's Hospital
Recruiting --> Active, not recruiting | N=48 --> 10 Trial completion date: Jul 2036 --> Jul 2039 | Trial primary completion date: Jul 2021 --> Jul 2024
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment change, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Apr 6, 2020
P1, N=48, Recruiting, Sponsor: Seattle Children's Hospital
Trial completion date: Jul 2036 --> Jul 2039 | Trial primary completion date: Jul 2021 --> Jul 2024 N=36 --> 48
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
Enrollment open, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Jun 20, 2018
P1, N=36, Recruiting, Sponsor: Seattle Children's Hospital
N=36 --> 48 Not yet recruiting --> Recruiting | Trial completion date: Apr 2035 --> Jun 2036 | Trial primary completion date: Apr 2020 --> Jun 2021
- | HER2-Specific CAR T / Cellevolve Bio, Seattle Children's Therapeutics
New P1 trial, CAR T-Cell Therapy, IO biomarker: HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov) - Apr 17, 2018
P1, N=36, Not yet recruiting, Sponsor: Seattle Children's Hospital